News

2020 News

Vancouver BC / NEWSWIRE / February 10, 2020 /CNW/ - Agrios Global Holdings Ltd. (CSE: AGRO) (OTCQB: AGGHF) (FSE: ØSA - WKN-A2N62K) ("Agrios" or the "Company") is pleased to announce the addition of Mr. Stewart B. Wasson and Mr. Douglas Bouldin to Agrios’ Board of Directors.

Mr. Wasson, a graduate of Purdue University is a pharmacist who began his career with Walgreens upon graduation. During his diverse and distinguished 33-year tenure, he has demonstrated success in creating multi-billion-dollar value through disruptive innovation and commercialization in the areas of retail, pharmacy, and healthcare.

During his tenure with Walgreens, Mr. Wasson has held several significant senior positions including Vice President of Pharmacy Operations and Retail Clinical Services, Group Vice President of Specialty Solutions Group and Group Vice President of Health Innovations. His group was instrumental in launching many retail-health offerings, such as the retail pharmacy-based US immunization program, leading to over 100 million vaccinations given to date and an additional 50 million globally through the “Get a Shot, Give a Shot” marketing campaign. Mr. Wasson brings to Agrios a solid understanding and experience of the healthcare ecosystem and the commercialization of products and services. Currently, he is an active Board Member and Advisory Board Member of several innovative health tech companies in the USA.

Mr. Bouldin is a graduate of the University of Missouri – St. Louis & Drury University – Springfield, MO. Mr. Bouldin, in addition to practicing medicine as a Family Nurse Practitioner for over three decades, is the Nurse Practitioner for The Ozzie Smith IMAC Regeneration Center in St. Louis Missouri.  Mr. Bouldin has served patients across a broad range of settings, at some of the most prestigious medical facilities in the State of Missouri including St. Luke’s Hospital, St. John’s Mercy, and Barnes Jewish Medical Group. His experience in both clinical and management roles has equipped him to serve as a leader in the recent ground-breaking efforts to revise the perception and role of cannabis for medicinal use.

“I welcome both Stewart and Douglas to the Board of Directors, their extensive experience in their respective fields will be invaluable in the execution of our strategic growth plans for the coming year” stated Chris Kennedy, President & CEO.

The Company has granted incentive stock options (the “Options”) to purchase up to 475,000 common shares of the Company to directors and a consultant of the Company. The Options are subject to the terms of the Company’s stock option plan and are exercisable for a period of two to five years at C$0.20 per share.

Additionally, the Company announces that it has filed documentation with the Canadian Securities Exchange (the “Exchange”) to amend the terms of an aggregate of 226,279 common share purchase warrants (the “Warrants”) issued pursuant to a non-brokered private placement (the “Private Placement”) which closed on February 20, 2018. The Warrants originally issued are exercisable into common shares in the capital of the Company at an exercise price of $0.25 per common share, with the Warrants expiring on February 20, 2020.  These Warrants will be amended by extending the expiry date of the Warrants to February 20, 2021.   

About Agrios Global Holdings Ltd.
Agrios Global Holdings is a data analytics-driven agriculture technology and services company advancing the latest innovations in indoor growing science. The Company owns, leases and manages properties and equipment for eco-sustainable agronomy and provides advisory services to support all aspects of aeroponic cultivation in the cannabis sector. Agrios is actively pursuing new opportunities to expand its portfolio of tenant growers and infrastructure assets in strategic licensed jurisdictions. Based in Vancouver, BC. Agrios is managed by a highly accomplished team of experienced industry and capital markets experts who are committed to the growth of the company.

For further information please contact:

Ute Koessler
T: 604-336-2444
investor@agriosglobal.com

This news release was prepared by management of Agrios, which takes full responsibility for its contents. The Canadian Securities Exchange ("CSE") has not reviewed and does not accept responsibility for the adequacy of this news release.  Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Agrios' periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related to corporate strategy and Agrios’ ability to execute such strategy, future developments regarding Agrios’ expansion into various markets including numerous states within the United States of America, and into Asia, expected costs of hemp fiber, intended development and sales of hemp products, market demand for hemp products, and the business and operations of Agrios as it relates to the Yunnan Province

Although Agrios has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US Federal laws; change in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Agrios disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Agrios does not assume any liability for disclosure relating to any other company mentioned herein.

Subscribe for email updates